What happened Shares of BioCryst (BCRX 0.00%), a biopharmaceutical company, are falling after the company reported third-quarter earnings results. A drop in top-line revenue and softer-than-expected guidance aren't sitting well with investors, who have driven the stock 16.5% lower as of 11:50 a.m. on Wednesday.
Is BIOC stock a good buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: BIOC) stock is to Strong Buy BIOC stock.
Will biocept stock go back up?
Biocept holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks....Predicted Opening Price for Biocept of Monday, June 6, 2022.Fair opening price June 6, 2022Current price$1.41$1.41 (Overvalued)
Will BIOC reverse split?
Biocept's common shares will continue to trade under the ticker symbol "BIOC." Authorization for the reverse stock split was approved by the Company's stockholders at Biocept's 2020 Annual Meeting of Stockholders.
Will biocept go up?
Biocept Inc quote is equal to 1.460 USD at 2022-05-29. Based on our forecasts, a long-term increase is expected, the "BIOC" stock price prognosis for 2027-05-21 is 5.153 USD. With a 5-year investment, the revenue is expected to be around +252.95%. Your current $100 investment may be up to $352.95 in 2027.
Should I buy or sell Biocept stock right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 2 buy ratings for t...
What is Biocept's stock price forecast for 2022?
2 Wall Street analysts have issued 1 year target prices for Biocept's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipat...
How has Biocept's stock price performed in 2022?
Biocept's stock was trading at $3.62 at the start of the year. Since then, BIOC stock has decreased by 60.5% and is now trading at $1.43. View the...
When is Biocept's next earnings date?
Biocept is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for Biocept .
How were Biocept's earnings last quarter?
Biocept, Inc. (NASDAQ:BIOC) released its quarterly earnings data on Monday, May, 23rd. The medical research company reported ($0.16) earnings per s...
When did Biocept's stock split? How did Biocept's stock split work?
Biocept's stock reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of sha...
Who are Biocept's key executives?
Biocept's management team includes the following people: Mr. Samuel D. Riccitelli , Interim Pres, CEO & Chairman (Age 63, Pay $67.24k) Mr. Anton...
What is Michael Nall's approval rating as Biocept's CEO?
1 employees have rated Biocept CEO Michael Nall on Glassdoor.com . Michael Nall has an approval rating of 100% among Biocept's employees. This put...
Who are some of Biocept's key competitors?
Some companies that are related to Biocept include Centogene (CNTG) , Sera Prognostics (SERA) , Psychemedics (PMD) , OpGen (OPGN) , Vyant Bio...
Who is the CEO of Biocept?
1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What is the biocept symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
What is the P/E ratio of Biocept?
The P/E ratio of Biocept is 17.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.38.
When is Biocept 1-10 split?
The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.
Is Biocept a buy or sell company?
Biocept has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Does Biocept pay dividends?
Biocept does not currently pay a dividend.
Shares of the small molecular diagnostics specialist took a beating after it announced an infrequently used method to raise cash
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of small molecular diagnostics company Biocept, Inc. ( NASDAQ:BIOC) are plummeting today, down 21.5% as of 11:53 a.m. EDT, following its announcement of a proposed rights offering. The decline marked a quick change of direction after Biocept's share price more than doubled on Wednesday.
So what
If all this sounds complicated, it's because it is pretty complicated. Rights offerings are one of several ways for companies to raise cash. However, they're not used as nearly as frequently as stock offerings. A key advantage of a rights offering compared to a stock offering is that it doesn't cause dilution of the value in existing shares.
Now what
Current Biocept shareholders will have to soon decide what to do with their subscription rights. They can exercise them, which means shelling out more money to buy Biocept preferred stock. The other option is to let the rights expire. Which step should be taken depends on your view of the company's prospects.
When will Biocept release results?
(Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and six months ended June 30, 2021 after the market closes on Monday, August 16, 2021.
When is Biocept's earnings call 2021?
NEW YORK, NY / ACCESSWIRE / May 12, 2021 / Biocept, Inc. (NASDAQ:BIOC) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 4:30 PM Eastern Time.
When is Biocept 2021?
(Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time).
Is BioCryst revenue lower than second quarter?
BioCryst reported total third-quarter revenue that was significantly lower than during the second quarter.
Does Cory Renauer have a position in any of the stocks mentioned?
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.